<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00644592</url>
  </required_header>
  <id_info>
    <org_study_id>302-2007</org_study_id>
    <nct_id>NCT00644592</nct_id>
  </id_info>
  <brief_title>LXRA Gene Polymorphisms and Response to Fenofibrate</brief_title>
  <official_title>LXRA Gene Polymorphisms and Response to Fenofibrate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American College of Clinical Pharmacy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a research study of how a cholesterol medication known as fenofibrate works
      differently in people with different genetic backgrounds. &quot;Genetics&quot; refers to certain things
      that are passed to a person by their parents, such as eye color or hair color. Genetic
      differences lead to people having different eye and hair color. There are also genetic
      differences in a protein called liver X receptor-alpha (LXRA), which may be important in
      predicting the response to fenofibrate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double blind crossover study of fenofibrate vs. placebo in healthy volunteers. The
      null hypothesis is that over a four week period, fenofibrate (160mg/day orally) is equivalent
      to placebo in terms of relative changes in cytokines ENA-78 and MCP-1 over a four week
      periods, separated by a four week washout. ENA-78 is a marker of inflammation. See
      http://en.wikipedia.org/wiki/CXCL5 for more details.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    supply issues with the formulation of fenofibrate that was used.
  </why_stopped>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Log(ENA-Period 2 End/ENA Period 1 End)</measure>
    <time_frame>week 12 to week 4</time_frame>
    <description>Log of the ratio of Period end ENA-78 Period 2:Period 1. Once the confidence interval is obtained, we take antilogs to obtain a ratio of effects.
Natural logs used</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1-Fenofibrate then Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 weeks of drug at 160 mg orally per day, 4 week washout, then 4 weeks of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Placebo then Fenofibrate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 weeks of placebo then 4 week washout then 4 weeks of Fenofibrate at 160 mg/day orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibrate capsule daily for 4 weeks</intervention_name>
    <description>Placebo capsule daily for 4 weeks</description>
    <arm_group_label>1-Fenofibrate then Placebo</arm_group_label>
    <arm_group_label>2 Placebo then Fenofibrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibrate</intervention_name>
    <description>160 mg/day orally for 4 weeks</description>
    <arm_group_label>1-Fenofibrate then Placebo</arm_group_label>
    <arm_group_label>2 Placebo then Fenofibrate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Triglycerides equal to or above 150mg/dL or Low HDL (below 44 mg/dl for men or below
             54 mg/dl for women)

          -  Must be able to swallow tablets

        Exclusion Criteria:

          -  Known Coronary Heart Disease, symptomatic carotid artery disease, abdominal aortic
             aneurysm, diabetes, or Framingham risk score above 20%

          -  Pregnancy, malignancy, liver dysfunction, renal dysfunction, active alcohol abuse,
             history of unexplained muscle pain

          -  Current treatment with lipid lowering therapy, estrogens, androgens, progestins,
             thiazide diuretics, beta-blockers, glucocorticoids (other than inhaled),
             antihistamines, or chronic anti-inflammatory drugs

          -  Current treatment with the following the interacting drugs: ursodeoxycholic acid,
             ursodiol, cholestyramine, red yeast rice, glyburide, glipizide, warfarin, or
             cyclosporine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Issam Zineh, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida College of Pharmacy, Department of Pharmacy Practice, Center for Pharmacogenomics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida College of Pharmacy, Center for Pharmacogenomics</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2008</study_first_submitted>
  <study_first_submitted_qc>March 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2008</study_first_posted>
  <results_first_submitted>March 12, 2012</results_first_submitted>
  <results_first_submitted_qc>May 23, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 24, 2012</results_first_posted>
  <last_update_submitted>May 24, 2012</last_update_submitted>
  <last_update_submitted_qc>May 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>UF Clinical Research Center. Started March 2008, completed August 2009.</recruitment_details>
      <pre_assignment_details>Patients were screened for eligibility.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>1-Fenofibrate Then Placebo</title>
          <description>4 weeks of drug at 160 mg orally per day</description>
        </group>
        <group group_id="P2">
          <title>2 Placebo Then Fenofibrate</title>
          <description>4 weeks of placebo then 4 week washout then 4 weeks of Fenofibrate at 160 mg/day orally.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1-Fenofibrate Then Placebo</title>
          <description>4 weeks of drug at 160 mg orally per day</description>
        </group>
        <group group_id="B2">
          <title>2 Placebo Then Fenofibrate</title>
          <description>4 weeks of placebo then 4 week washout then 4 weeks of Fenofibrate at 160 mg/day orally.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.2" spread="17.1"/>
                    <measurement group_id="B2" value="26.0" spread="6.6"/>
                    <measurement group_id="B3" value="27.5" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Log(ENA-Period 2 End/ENA Period 1 End)</title>
        <description>Log of the ratio of Period end ENA-78 Period 2:Period 1. Once the confidence interval is obtained, we take antilogs to obtain a ratio of effects.
Natural logs used</description>
        <time_frame>week 12 to week 4</time_frame>
        <population>Intent was to enroll 30 but drug was withdrawn by provider, with only 11 completing both experimental periods</population>
        <group_list>
          <group group_id="O1">
            <title>1-Fenofibrate Then Placebo</title>
            <description>4 weeks of drug at 160 mg orally per day</description>
          </group>
          <group group_id="O2">
            <title>2 Placebo Then Fenofibrate</title>
            <description>4 weeks of placebo then 4 week washout then 4 weeks of Fenofibrate at 160 mg/day orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Log(ENA-Period 2 End/ENA Period 1 End)</title>
          <description>Log of the ratio of Period end ENA-78 Period 2:Period 1. Once the confidence interval is obtained, we take antilogs to obtain a ratio of effects.
Natural logs used</description>
          <population>Intent was to enroll 30 but drug was withdrawn by provider, with only 11 completing both experimental periods</population>
          <units>Log of Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.298" spread="0.31"/>
                    <measurement group_id="O2" value="0.178" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This is a crossover analysis. To convert to a ratio effect, the mean difference must be divided by two and antilogs take. The outcome represents a relative effect.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.015</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Ratio of mean effects</param_type>
            <param_value>1.27</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.16</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.06</ci_lower_limit>
            <ci_upper_limit>1.52</ci_upper_limit>
            <estimate_desc>The estimated mean log difference (SE) between the period 2 and period 1 effects and SE was estimated. This estimates twice the effect size[since (B-A)-(A-B)=2B-2A] so the actual estimate was based upon the antilog of half of this difference.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 Weeks on Treatment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>1-Fenofibrate</title>
          <description>4 weeks of drug at 160 mg orally per day</description>
        </group>
        <group group_id="E2">
          <title>2 Placebo</title>
          <description>4 weeks of placebo.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>SNOMED CT</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal</sub_title>
                <description>Abdominal Complaints</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Nausea/Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <description>Skin rash</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Reginald F. Frye, PhD, Associate Professor</name_or_title>
      <organization>University of Florida</organization>
      <phone>3522735453</phone>
      <email>fryerf@ufl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

